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doi:10.1016/j.jtcvs.2007.06.039Objective: Various tissue-engineered vascular grafts have been studied to overcome
the clinical disadvantages of conventional prostheses. Previous tissue-engineered
vascular grafts have generally required preoperative cellular manipulation or use of
bioreactors to improve performance, and their mechanical properties have been
insufficient. We focused on the concept of in situ cellularization and developed a tis-
sue-engineered vascular graft for arterial reconstruction that would facilitate renewal
of autologous tissue without any pretreatment.
Methods: The graft comprised an interior of knitted polyglycolic acid compounded
with collagen to supply a scaffold for tissue growth and an exterior of woven poly-
L-lactic acid for reinforcement. All components were biocompatible and biodegrad-
able, with excellent cellular affinity. The grafts, measuring 10 mm in internal diameter
and 30 mm in length, were implanted into porcine aortas, and their utility was eval-
uated to 12 months after grafting.
Results: All explants were patent throughout the observation period, with no sign of
thrombus formation or aneurysmal change. Presence in the neomedia of endothelial-
ization with proper integrity and parallel accumulation of functioning smooth muscle
cells, which responded to vasoreactive agents, was confirmed in an early phase after
implantation. Sufficient collagen synthesis and lack of elastin were quantitatively
demonstrated. Dynamic assessment and long-term results of the in vivo study indi-
cated adequate durability of the implants.
Conclusion: The graft showed morphologic evidence of good in situ cellularization,
satisfactory durability to withstand arterial pressure for 12 postoperative months,
and the potential to acquire physiologic vasomotor responsiveness. These results sug-
gest that our tissue-engineered vascular graft shows promise as an arterial conduit
prosthesis.
A
rtificial vascular grafts manufactured from synthetic materials, for example
polyester and expanded polytetrafluoroethylene (ePTFE), have been rou-
tinely used to reconstruct blood flow in patients with various cardiovascular
disorders. Conventional grafts have clinically shown satisfactory durability; however,
they still have several disadvantages, such as thrombogenicity, late stenosis and oc-
clusion from intimal hyperplasia (especially in small caliber grafts), susceptibility
to infection, and lack of growth potential.1,2 To overcome these limitations in the
search for an ideal artificial graft, various tissue-engineered vascular grafts (TEVGs)
have been developed.3 The utility and the clinical experience of these new grafts have
been reported.4-6 In TEVGs, a biodegradable polymer or a decellularized biomaterial
is commonly used as a scaffold to enable host cells to rebuild the vessel architecture,
and autologous cell seeding and culture or growth with bioreactors before the opera-
tion is usually necessary to improve their antithrombogenicity and performance.1,2,
7-11 These pretreatments involve complicated and invasive procedures, potentially
leading to infection, and also require a certain period to complete, which means
that pretreated TEVGs are not always available or may be unsuitable for an emergency
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ePTFE 5 expanded polytetrafluoroethylene
HUVEC 5 human umbilical vein endothelial cell
PGA 5 polyglycolic acid
PLLA 5 poly-L-lactic acid
SMC 5 smooth muscle cell
SNP 5 sodium nitroprusside
TEVG 5 tissue-engineered vascular graft
case.5 Furthermore, use of TEVGs has been mostly limited to
low-pressure conditions because of their poor durability.5,6,12
For these reasons, we focused on the concept of in situ
cellularization, whereby a population of living host cells is
achieved in situwithout any pretreatment by supplying a scaf-
fold to support tissue self-renewal. This scaffold acts as an in
situ incubator and bioreactor. Chen and colleagues13 realized
this concept in the regeneration of bovine chondrocytes by
using a biocompatible material with excellent cellular attach-
ment properties. We recently developed two promising novel
patches for cardiovascular repair, a poly(lactic-co-glycolic
acid) and collagen patch14 and a tissue-engineered patch,15
both of which showed good in situ cellularization in vessel
wall reconstruction of large animal models. We hypothesized
that an entire tubular graft fabricated from our patch would be
an ideal vascular prosthesis that could acquire favorable mor-
phologic features and also intrinsic vascular function
matched to the native artery by means of in situ cellulariza-
tion. This kind of TEVG has not yet been reported.
In this study, we designed a TEVG for arterial reconstruc-
tion that was expected to facilitate regeneration of autologous
tissue without any pretreatment and assessed in situ cellulari-
zation after implantation in a porcine model. We also evalu-
ated whether the implanted TEVG possessed adequate
durability to withstand the hemodynamic stress of the sys-
temic circulation in a long-term follow-up model and had
acquired the physiologic vasoreactivity inherent in an artery.
Materials and Methods
Graft Design and Cellular Affinity
The new vascular prosthesis was made from a tissue-engineered
patch15 recently developed in our laboratory with greater biocom-
patibility and mechanical strength than previous materials used for
cardiovascular repair. The patch has a three-layered structure: the in-
terior (luminal side) is composed of knitted polyglycolic acid (PGA)
compounded with collagen microsponge, the middle layer is poly-
caprolactone, and the exterior is composed of woven poly-L-lactic
acid (PLLA; Figure 1A). It was provided by Senko Medical Instru-
mentMfg Co Ltd (Tokyo, Japan). All these materials are biocompat-
ible and biodegradable and have received Food and Drug
Administration clearance. The internal 3-dimensional porous struc-
ture of knitted PGA and collagen microsponge is expected to play
a crucial role as a scaffold promoting in situ cellularization. The
tightly woven layer of PLLA on the outside reinforces the patch,38 The Journal of Thoracic and Cardiovascular Surgery c Julyand a polycaprolactone film binds the PGA and PLLA layers to
each other. Degradation tests (37C) of the synthetic polymers,
mainly involving hydrolytic reactions, demonstrated that the
mechanical strength of PGA was no longer adequate by 3 weeks,
whereas PLLA was degraded so slowly that its strength was main-
tained through 6 months.
Cell culture tests were performed to evaluate cellular affinity and
proliferation in the materials used in this study. Two lines of cells,
human umbilical vein endothelial cells (HUVEC; Cambrex Corpo-
ration, East Rutherford, NJ) and murine fibroblasts (NIH3T3; Amer-
ican Type Culture Collection, Manassas, Va) were seeded at
a density of 300 cells/mm2 onto knitted PGA with or without colla-
gen microsponge, woven PLLA, and ePTFE (GoreTex; Japan Gor-
eTex Inc, Tokyo, Japan) (n 5 6), then cultured at 37C at 100%
humidity and in a 5% carbon dioxide atmosphere. The culture me-
dium was Dulbecco modified Eagle medium (Gibco; Invitrogen
Corporation, Carlsbad, Calif) supplemented with 10% fetal bovine
serum (Sigma Chemical Co, St Louis, Mo) and 1% penicillin and
streptomycin (Invitrogen). After 3 days of culture, the number of
cells attached to each material was counted by a water-soluble tetra-
zolium assay (Dojindo Laboratories, Kumamoto, Japan).
Implantation in Porcine Models
A tissue-engineered patch was manually formed into a tubular shape
with continuous 5-0 Prolene sutures (Ethicon, Inc, Somerville,NJ).
Figure 1. A, Scaffold design of polyglycolic acid/poly-L-lactic acid
graft. Graft wall had three-layered structure: luminal side, knitted
polyglycolic acid compounded with collagen microsponge; middle
layer, polycaprolactone; outside, woven poly-L-lactic acid. B, Im-
plantation of graft into porcine aorta. Scale bar represents 10 mm.2008
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and 30 mm in length. We implanted these grafts into the thoracic
descending aorta of Crownminipigs (12–20 kg; Figure 1B). General
anesthesia was induced by means of intramuscular bolus injection
of 20-mg/kg ketamine (Sankyo Co, Tokyo, Japan) and 2-mg/kg
xylazine (Bayer Medical Co, Tokyo, Japan) and maintained with a
continuous intravenous infusion of 8-mg/(kg $ h) propofol (Astra-
Zeneca, Osaka, Japan) and additional injections of ketamine at 10
mg/(kg $ h). The aorta was approached through a left posterolateral
thoracotomy. After systemic heparinization (100 IU/kg), the aorta
was clamped and resected, and simultaneously a shunt circuit was
established to prevent paraplegic complications. Proximal and distal
anastomoses were then performed with 5-0 Prolene running sutures.
No anticoagulants or antiplatelet agents were given after the opera-
tion. The animals were randomly divided into five groups, and the
vascular prostheses were retrieved when the animals were killed at
1 (n 5 2), 2 (n 5 4), 4 (n 5 5), 6, and 12 months (n 5 4) after
implantation. Five ePTFE grafts of the same size as the PGA/PLLA
grafts were implanted in a similar manner and harvested (2, 4, and 6
months after implantation, n5 1, n5 3, and n5 1, respectively) as
controls. All pigs received humane care and treatment in accordance
with the ‘‘Guide for the Care and Use of Laboratory Animals’’
(www.nap.edu/catalog/5140.html).
Tissue Assessment
Explanted grafts were opened longitudinally and then photo-
graphed as gross specimens. The macroscopic endothelial cover-
age rate on the inner surfaces of the grafts was calculated with
the image analysis software package Scion Image (Scion Corpora-
tion, Frederick, Md). Part of the specimen prepared in a typical
fashion was analyzed by scanning electron microscopy (S-800;
Hitachi, Ltd, Tokyo, Japan). We also measured the wall thickness
of the neotissue, which was defined as regenerated tissue compris-
ing newly organized autologous cells inside the PLLA layer. A
longitudinal section of the harvested grafts was processed for
histologic evaluation and was examined by double staining with
hematoxylin and eosin and Victoria blue stains for elastic fibers.
Immunohistologic staining was performed to identify cell types
and matrices in the regenerated tissue. The antibodies used were
monoclonal antibodies against a–smooth muscle actin (DAKO
Corporation, Carpenteria, Calif) and collagen type IV (DAKO)
and a polyclonal antibody against von Willebrand factor (rabbit;
DAKO) for endothelial cells.
The content of representative extracellular matrices was bio-
chemically quantified with the regenerated tissue alone. The colla-
gen content was measured with a 4-hydroxyproline assay. The
elastin content was measured by determining the dry weight of the
insoluble material after delipidation in acetone-diethylether and
solubilization in 0.1-N sodium hydroxide at 98C. We compared
the measured amounts in each group with those from native aortas
(n 5 19).
The maximal tensile strength of residual PLLA layers taken from
the explants was measured with a TENSILON mechanical tester
(ORIENTEC Co, Tokyo, Japan). Samples of size 20 3 10 mm
were used, with an initial crosshead span of 10 mm and a speed of
10 mm/min. The strength was represented in newtons.
The vasomotor responsiveness of the retrieved PGA/PLLA
grafts was examined both qualitatively and quantitatively. Prosthe-
ses explanted 2 months after implantation (n5 2) were immediatelyThe Journal of Thplaced for preservation into ice cold Krebs solution.16 The regener-
ated tissue was carefully dissected from the explants and cut into
cross-sectional segments of 20 3 5 mm. We observed the morpho-
logic changes in suspended segments at 37C on direct administra-
tion of 1023-mol/L norepinephrine (Sankyo) and sodium
nitroprusside (SNP; Maruishi Pharmaceutical Co, Osaka, Japan)
as previously described.17 To quantify the responses, standard iso-
metric tension experiments were performed.16 Briefly, 10 3 5-
mm segments prepared from 2- and 12-month models were
stretched to an initial tension of 8 g and then allowed to equilibrate
for 2 hours in an organ chamber (37C) containing oxygenated
Krebs solution. All the following experiments were done in the pres-
ence of 1025-mol/L indomethacin (Sigma). Contractile responses to
increasing concentrations of norepinephrine were measured and ex-
pressed in milligrams. To investigate endothelium-independent re-
laxation, the segments were contracted in advance with 1025 mol/L
norepinephrine so that a stable baseline of contraction was achieved,
then the dose-response curve to SNP was determined. The relaxa-
tion responses were expressed as the percentage reduction in the ten-
sion produced by 1025-mol/L norepinephrine. Matched segments of
native aortas (n 5 5) were used as controls.
Statistical Analysis
All results are expressed as mean6 SEM. Cell culture tests were an-
alyzed with the Student t test. Comparisons of measured data among
multiple groups were performed with appropriate analysis of vari-
ance and the Tukey–Kramer post hoc test. In all statistical analyses,
the commercially available software package StatView (SAS Insti-
tute, Inc, Cary, NC) was used.
Results
Cellular Affinity
With both cell lines, culture tests showed that the number of
cells attached to knitted PGAwith collagen microsponge was
significantly greater than that without collagen (HUVEC
with collagen 1566 6 191 cells/mm2 and without collagen
1168 6 137 cells/mm2, P 5 .0020, NIH3T3 with collagen
2337 6 550 cells/mm2 and without collagen 1859 6 342
cells/mm2, P 5 .0418). This suggests that the presence of
compounded collagen microsponge increased the cellular
adhesion properties of knitted PGA. The cellular affinity of
woven PLLA (HUVEC 716 6 56 cells/mm2, NIH3T3
15176270 cells/mm2) was less than that of PGA. The num-
bers of cells attached to ePTFEwere 2316 73 and 5916 151
cells/mm2 for HUVEC and NIH3T3, respectively, indicating
that PGA and PLLA have a significantly higher cellular affin-
ity than ePTFE. These results were verified by scanning elec-
tron microscopy (data not shown).
Implantation Results
All the operations were completed successfully, with negligi-
ble bleeding through the walls of the implanted PGA/PLLA
grafts after declamping of the aorta. All animals survived
without any postoperative complications during the predeter-
mined observation period.oracic and Cardiovascular Surgery c Volume 136, Number 1 39
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On gross inspection, each explanted graft was patent, with no
sign of thrombus or aneurysm formation. The luminal sur-
faces of all grafts, even those in the 1-month group, were uni-
formly smooth and glistening, as in native aorta. The surfaces
were completely endothelialized macroscopically. In ePTFE
grafts, however, there was always some endothelial defect
into which blood had soaked (Figure 2). The incidence of
such defects was not associated with the duration of implan-
tation, and the overall mean value of the endothelial coverage
rate was 82.6% 6 21.0% (46.5%–97.0%). The implanted
grafts were surrounded by fibrous connective tissue, and
none of the grafts had a severely stiffened wall. The PGA
component could not be found macroscopically, whereas
the PLLA layers were obvious in all specimens.
Morphologic Examinations
Scanning electron micrography. Scanning electron mi-
crography revealed that the luminal surfaces of the PGA/
PLLA grafts 2 months after implantation were covered
with confluent and cobblestonelike cells that were oriented
parallel to the direction of blood flow, although they were
aligned irregularly in places (Figure 3, A). After 6 months,
confluent endothelial cells with prominent nuclei formed an
orderly alignment on the intima (Figure 3, B and C). In the
macroscopic endothelial defects in ePTFE grafts, ePTFE
fibrils were directly exposed to the lumen without any endo-
thelial coverage; instead, a number of blood cells were
attached to the defective surface (Figure 3, D).Wall thickness of neotissue. The neotissue in the 2-month
group had a thickness of approximately 1.5 mm at each point,
although the measured values were somewhat widely distrib-
uted (Figure E1). After this time, there were no significant
differences in thickness at any point among the groups, indi-
cating no tendency for wall thickness to increase in a time-
dependent manner. When the three measured points were
compared within each group, there were no significant differ-
ences.
Histologic and immunohistochemical examinations.
The histologic findings in each model are shown in Figure 4.
We mainly observed sections featuring the middle portion,
into which transanastomotic ingrowth of autologous cells
would be relatively difficult. Immunohistochemically, von
Willebrand factor–positive endothelial monolayers were
already confirmed along the whole length of the luminal
surfaces at 1 month. Beneath the endothelium, numerous
smooth muscle cells (SMCs) were piled up in parallel, as
seen in native media. Such good cellularization with the
two types of cells in PGA/PLLA grafts was similarly found
in the other groups. Extracellular matrix in the subendothelial
layers was stained faintly by Victoria blue, but the intensity
of the stain increased with time, and fiberlike structures con-
sistent with elastic fibers were detected in long-term models.
The PGA component of the grafts was degraded and
absorbed almost completely by 2 postoperative months,
whereas the PLLA was relatively intact and maintained its
layered structure to 12 months. In the early phase, mild infil-
tration of inflammatory cells and phagocytic phenomenaFigure 2. Upper row, Macroscopic findings of polyglycolic acid/poly-L-lactic acid grafts at 1 (A), 2 (B), 4 (C), 6 (D),
and 12 (E) months after implantation. All explants were patent, with no sign of thrombus or aneurysm formation, and
all surfaces were completely endothelialized. Lower row: macroscopic findings of expanded polytetrafluoroethy-
lene grafts at 2 (F), 4 (G), and 6 (H) postoperative months. Endothelial defects were always detected. Scale bar
represents 5 mm.
40 The Journal of Thoracic and Cardiovascular Surgery c July 2008
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CDFigure 3. Scanning electron micrographs of lumi-
nal surfaces of polyglycolic acid/poly-L-lactic
acid grafts 2 (A), 6 (B), and 12 (C) months after
grafting. Surfaces were covered with confluent
endothelial cell lining parallel to direction of
blood flow. D, Scanning electron micrograph of
endothelial defect in expanded polytetrafluoro-
ethylene graft. Direct exposure of its fibrils to
graft lumen was observed. Original magnification
3800; scale bar, 20 mm. Arrows indicate direction
of blood flow.were observed around the remnants of each material. Immu-
nohistochemical testing for collagen type IV demonstrated
positively stained layers, showing the existence of basal
membrane, just below the endothelium in all the newly devel-
oped grafts. We also detected scattered positive staining in
the neomedia, suggestive of vasa vasorum in the newly
formed tissue (Figure E2). Microscopic examination of the
ePTFE grafts showed only partial regeneration of autologous
tissue on the surfaces.
Biochemical Evaluation
The 4-hydroxyproline assay revealed that the amount of col-
lagen in the neotissue increased in proportion to the duration
of implantation. At 6 months after implantation, the collagen
content was equivalent to that in native aorta (Table 1). The
elastin content increased slightly with time but after 4 months
had reached a plateau at approximately a third of the native
level (Table 1).
Mechanical Properties
The maximum tensile strengths of the remaining PLLA
layers were 51.5 6 7.9, 66.6 6 3.6, 55.4 6 8.1, 39.8 6
7.3, 26.6 6 19.4, and 25.4 6 8.7 N before implantationThe Journal of Th(n5 6) and in the 1-, 2-, 4-, 6-, and 12-month groups, respec-
tively. The strength was significantly diminished in a time-
dependent manner. The mechanical strengths of the PLLA
layers taken from 6- and 12-month specimens were greater
than that of native aorta (8.3 6 4.6 N, n 5 6), although the
differences were not statistically significant.
Vascular Function
As shown in Figure 5, A, samples derived from the 2-month
group were suspended to form an arch shape. This shape be-
came an open arch when norepinephrine was administered
then closed on administration of SNP, indicating contraction
and relaxation, respectively. These pharmacologic responses
were repeatedly observed. The contractile activities of 2- and
12-month specimens in the standard isometric experiments
are shown in Figure 5, B. Both groups exhibited dose-
response curves to norepinephrine, and the contractile force
in the 12-month group was significantly greater than that in
the 2-month group. The maximal contractile force (norepi-
nephrine 1024 mol/L) in the 12-month model was 430 6
21 mg, 16.3% of that in native aorta (26426 189 mg) under
the same conditions. We also observed dose-dependentoracic and Cardiovascular Surgery c Volume 136, Number 1 41
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model. Left: immunohistochemical dou-
ble staining for von Willebrand factor
(vWF) and a–smooth muscle actin (al-
pha-SMA). Right, Double staining with
hematoxylin and eosin (H&E) and Victo-
ria blue stain. Immunohistochemical
staining showed endothelial mono-
layers and parallel alignment of smooth
muscle cells beneath endothelium in all
polyglycolic acid/poly-L-lactic acid
graft models. Victoria blue–positive fi-
berlike structures consistent with elas-
tic fibers were detected in long-term
models. With expanded polytetrafluoro-
ethylene (ePTFE) grafts, good tissue re-
generation was not observed. Original
magnification 3100; scale bar, 100 mm.
B (2-month model) and C (12-month
model) show all layers of implanted
polyglycolic acid/poly-L-lactic acid
grafts stained immunohistochemically.
Asterisks represent space occupied by
remaining poly-L-lactic acid layers.
Original magnification 340; scale bar,
250 mm. D, Immunohistochemical find-
ings in 2-month model. Arrowheads in-
dicate endothelial monolayer. Original
magnification 3200; scale bar, 100 mm.
E, Hematoxylin and eosin stain of poly-
glycolic acid/poly-L-lactic acid graft 1
month after implantation. Mild infiltra-
tion of inflammatory cells and phago-
cytic giant cell were observed around
scaffold remnants in subendothelial
layer. Original magnification 3200;
scale bar, 100 mm.relaxation of each sample in response to SNP (Figure 5, C).
The percentage relaxations with 1024 mol/L SNP were
89.0% 6 20.7%, 70.5% 6 25.7%, and 95.6% 610.8% in
the 2- and 12-month groups and the positive controls, respec-
tively, with no significant differences. There was no signifi-
cance difference in relaxation response to SNP between the
2- and 12-month groups.
The time course of the regeneration process in PGA/
PLLA grafts is shown in Table E1.
Discussion
Many strategies have recently been attempted to facilitate
regeneration of autologous tissue on tissue-engineered
materials. A major method is preoperative cellular manipu-
lation.5,9,10 Kaushal and coworkers9 demonstrated func-
tional small diameter neovessels produced with
endothelial progenitor cells. Another effective method is
the use of a bioreactor.7-9,11 Campbell and associates8 sug-42 The Journal of Thoracic and Cardiovascular Surgery c Julygested that the host’s own peritoneal cavity is an effective
bioreactor and showed that it is feasible to grow vascular
prostheses within it. Also, Hoerstrup and colleagues11 dem-
onstrated the growth capacity of cell-seeded TEVGs grown
in vitro for 21 days under biomimetic conditions. Although
we fully recognize the utility of these pretreatments, their
TABLE 1. Biochemical quantification of representative
extracellular matrices
Group Collagen content (mg/mg) Elastin content (mg/mg)
1 mo 115.6 6 9.3 51.6 6 46.8
2 mo 197.2 6 36.1 57.5 6 37.4
4 mo 179.1 6 98.0 130.2 6 82.0
6 mo 277.8 6 79.6 115.7 6 85.4
12 mo 267.8 6 88.7 158.2 6 107.8
Native aorta 238.8 6 48.1 427.2 6 64.8*
*P , .05 versus all other groups.2008
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tion, and the need for preparation time, have led to hesita-
tion in their clinical use. In this study, we used in situ
cellularization as an alternative method that would be
more suitable for clinical application because of its ready
availability.14,15 As a candidate material for our TEVG,
we focused our attention on a tissue-engineered patch
with good cellular attachment properties that could provide
a feasible microenvironment for vascular self-renewal.15
Cell counting proved that PGA/PLLA grafts had a much
higher cellular affinity than ePTFE grafts designed for the
same purpose.18
The PGA/PLLA grafts demonstrated good in situ cellula-
rization. The in vivo study produced the interesting observa-
tion that all the implanted PGA/PLLA grafts showed
complete endothelialization, whereas this was never seenThe Journal of Thwith any ePTFE graft, irrespective of the implantation period.
After experiments on vascular wall reconstruction with a tis-
sue-engineered patch, we previously reported that endotheli-
alization was complete by 1 month after grafting.15 Similarly,
in this study complete endothelialization was present by 1
month at least. Scanning electron micrography showed the
endothelial integrity of the luminal surfaces, and immunohis-
tochemical examination showed that the newly organized en-
dothelium was accompanied by a basal membrane. It is well
known that endothelialization yields antithrombogenic prop-
erties.9,10 The grafts were free of thrombus formation during
the observation period despite the lack of antiplatelet and
anticoagulant drugs. In ePTFE grafts, the direct exposure of
ePTFE fibrils to the graft lumen and the irregularity of the
graft surface at defective sites might cause local turbulence
of intraluminal blood flow, resulting in an incidentalFigure 5. A, Qualitative study of vasomotor responsiveness with neotissue obtained from 2-month model. Suspended
arch-shaped sample exhibited series of formation changes suggestive of relaxation and contraction on administra-
tion of sodium nitroprusside and norepinephrine, respectively. B, Contractile activities of 2-month (triangles) and
12-month (squares) models in isometric studies. Both models exhibited dose-response curves to norepinephrine.
Asterisk indicates P < .05 versus 2-month model. C, Relaxation responses of 2-month (triangles) and 12-month
(squares) models and native aortas (circles) in isometric studies. Data represent percentage reduction in precon-
traction with 1025-mol/L norepinephrine. In each model, dose-dependent relaxation to sodium nitroprusside was
demonstrated. Asterisk indicates P < .05 versus 2- or 12-month model. Double asterisk indicates P < .05 versus
12-month model.oracic and Cardiovascular Surgery c Volume 136, Number 1 43
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tion if a pathogen was present in host blood.
A population of numerous SMCs with parallel accumula-
tion in the subendothelial layers, as seen in native media, was
demonstrated. To determine whether the retrieved grafts had
a physiologic vascular function, we tested the contractile and
relaxation responses of the SMCs. At 2 months, the regener-
ated tissue already showed a reproducible pharmacologic
vasomotor reaction. The contractility in response to norepi-
nephrine increased in proportion to both the concentration
of the agent and the implantation period. The magnitude of
the maximal contractile force in the 12-month model was
equal to or greater than that in other pretreated TEVGs re-
ported on previously.7,8 In the relaxation studies with SNP,
similar dose-response curves were found in all examined
groups. The duration of implantation did not affect the relax-
ation of samples retrieved from PGA/PLLA grafts. These
responses suggest that SMCs in the neomedia could acquire
endothelium-independent vascular function to some extent as
a result of being grown in an in situ bioreactor. In addition,
we verified the existence of vasa vasorum in the neomedia,
reflecting the neovascularization essential for tissue growth.
Biochemical examination showed that collagen in the
neotissue was fully regenerated in the process of in situ cel-
lularization at 6 months after grafting. Sufficient collagen
to act as a framework might give the newly organized tissue
dynamic strength against the systemic pressure. Histologic
and biochemical evaluation, however, showed that the extent
of elastin remodeling had not reached that of the controls dur-
ing the experimental period. This implies that elasticity of the
neotissue might be insufficient relative to native tissue. We
speculate, on the basis of the morphologic observations,
that tissue regeneration by host cells on PGA/PLLA grafts
involving absorption of the biodegradable scaffolds was ac-
tive in the early phase and that the basic vascular architecture
was complete at 2 months after grafting. In the later phase, the
regeneration process seemed gradually to become inactive,
whereas neotissue remodeling, particularly by the extracellu-
lar matrix, progressed, as shown by the biochemical quanti-
fications. As a result, the walls of our TEVGs were of
almost constant thickness throughout the survey.
Considering the use of PGA/PLLA grafts for arterial inter-
vention, we needed to evaluate their postimplantation dura-
bility through long-term follow-up. The strength of the
PLLA layers, which are the major supporting factors in the
prostheses, should be gradually reduced after grafting as a re-
sult of hydrolysis and perhaps biologic processes, including
phagocytosis. In the in vivo implantation study, no case of
rupture or aneurysm formation was observed. The maximal
tensile strength of the remaining PLLA alone was even
greater than that of the native tissue throughout our observa-
tions. Also, the firm connective tissue surrounding the grafts,
which resulted from the wound healing process, would assist
in reinforcing them. Consequently, it is thought that the44 The Journal of Thoracic and Cardiovascular Surgery c Julyactual strength of the implanted grafts would exceed that of
native aortas. It remains unclear, however, whether the me-
chanical strength of a graft entirely replaced by autologous
tissue can be resistant to systemic pressure, and therefore
further long-term follow-up is required.
We selected the pig as an experimental model in this study
because its hemodynamics resemble those of human beings.
The systemic blood pressure of the animals was 100 to 140
mm Hg in the systolic phase and 50 to 90 mm Hg in the
diastolic phase. The graft length of 30 mm was determined
to avoid complete tissue regeneration simply by transanasto-
motic ingrowth of host cells.19 The detailed process of in situ
cellularization has not been elucidated in this study. It is cer-
tain, however, that the scaffold provided by the newly devel-
oped graft would be a more suitable microenvironment for
self-renewal of the vascular architecture thanwould a conven-
tional prosthesis if tissue regeneration, including endothelial-
ization, could not be achieved because of the predetermined
graft length. We speculated on other mechanisms of in situ
cellularization in which circulating progenitor cells would
fall into the scaffold more easily, or transmural ingrowth of
certain pericytes that guide vascular regeneration into the
scaffold would occur more readily, with subsequent differen-
tiation and proliferation according to the microenviron-
ment.8,9 In this experimental model, the implanted grafts
were grown in the native circulation system, which acted as
an in situ bioreactor. We therefore speculate that the proper
lining up of cells with high affinity on our TEVGs might
be achieved by a mechanism analogous to the healing process
in native vessels.
The limitations of our study are the lack of regenerated
elastin and the residual PLLA layers. We speculate that the
poor elastogenesis seen in implanted PGA/PLLA grafts
might occur because the remaining outer, stiff PLLA layer
prevents arterial pulsation and transmission of shear stress
to the graft wall. To resolve these limitations, it would be nec-
essary to modify the graft design so that the PLLA compo-
nent is completely degraded in a relatively early phase after
grafting or to apply substances that are known to accelerate
elastin synthesis, such as retinoic acid or calcitriol.20,21
Considering the established use of artificial grafts for aor-
tic surgery and the need for small-diameter prostheses, the
complete and early endothelialization demonstrated by our
TEVG is meaningful, particularly in the setting of small-
diameter vascular structures, such as peripheral arteries. In
future, two ways to optimize the self-renewing mechanism
should be considered. One is use of a TEVG that is com-
pletely replaced by autologous tissue. Assuming that the syn-
thetic materials were fully degraded and that satisfactory
remodeling of elastin was achieved, such a TEVG may
have considerable compliance. This is of great importance,
because the compliance of a graft, particularly of small diam-
eter, is closely associated with its patency.22 Another possi-
bility is a TEVG that is partially replaced by autologous2008
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in the mechanical properties of PGA/PLLA grafts, nonde-
gradable materials such as polyester, which can guarantee
constant adequate strength, could be used as alternatives to
PLLA. This kind of vascular graft would be expected to
exhibit especially well-regulated endothelialization matched
to the native vessel, reducing the risk of graft infection and
providing durability adequate to withstand the arterial pres-
sure throughout the host’s life. This application is also likely
to be suitable for medium- and large-diameter grafts, in
which elasticity is not so important clinically.
In conclusion, a PGA/PLLA graft showed evidence of
good in situ cellularization, including relatively early endo-
thelialization and population with functioning SMCs, after
implantation into porcine aorta. The graft was durable
enough to withstand high-pressure conditions for at least
12 postoperative months, despite the presence of a residual
PLLA layer, and also demonstrated the potential to acquire
intrinsic physiologic vascular function. Our novel vascular
graft would be a useful prosthesis even for arterial reconstruc-
tion, particularly in peripheral arterial surgery, andmight pro-
vide a wide variety of therapeutic options in cardiovascular
surgery.
We thankMr ShigeruMatsumi for excellent technical assistance.
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CDFigure E1. Wall thickness of neotissue formed in
implanted PGA/PLLA grafts. Thickness was mea-
sured at three points: 5 mm from proximal and dis-
tal anastomoses, respectively, and at midpoint of
graft. In all groups, mean value at each measured
point was approximately 1.5 mm.
Figure E2. Immunohistochemical examination for
collagen type IV 1 (A), 2 (B), 4 (C), and 6 (D) months
after implantation. Positively stained thin layers
just below endothelium and scattered positive
staining in subendothelial layers were seen. Orig-
inal magnification 3100; scale bar, 100 mm.
TABLE E1. Time course of regeneration process in
polyglycolic acid/poly-L-lactic acid grafts
1 mo 2 mo 4 mo 6 mo 12 mo
Endothelialization 1 1 1 11 11
Smooth muscle cells 1 1 (functioning) 1 1 11
Vasa vasorum 1 1 1 1 1
Polyglycolic acid 1 6 2 2 2
Poly-L-lactic acid 1 1 Y YY YY
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